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Introduction
Epilepsy is a chronic neurological disorder that affects around 50 million people worldwide (Nei and Heys, 2010) . Since the clinical introduction of the first antiepileptic drug (AED) appreciable efforts have been carried out in order to improve the quality of life of the patients.
Today, a wide therapeutic range of AEDs with various activity spectra and tolerability profiles is available (Bialer, 2012a) . Nevertheless, the truth is that the new AEDs developed so far are not completely effective since only 70% of the epileptic patients become seizure free when administered with one of those drugs. In opposition, the remaining 30% of the patients often develop a chronic form of epilepsy that is refractory to several pharmacological treatments (Brodie, 2005; Luszczki, 2009) . Thus, the discovery of new AEDs still remains a ceaseless challenge for the medicinal chemistry and pharmacology (Bialer and White, 2010; Mackey, 2010; Schmidt 2010 Schmidt , 2011 .
One of the techniques that has become commonplace for searching novel AEDs is based on chemical and/or structural modifications of currently available AEDs, in order to obtain more effective drugs with better pharmacokinetic properties than the available maternal AED (Rogawski, 2006; Bialer, 2010; Bialer and White 2010; Bialer 2012) . As recently emphasized by Bialer (2012a) , pharmacokinetic-based design of AEDs has been carried out to enhance the absorption, plasma exposure and brain penetration of the active entity and/or circumvent the formation of toxic metabolites. Bearing this in mind and the fact that almost 40% of the drug candidates fail during preclinical phases due to their inadequate pharmacokinetic properties (Yengi et al., 2007) , rational design approaches should be applied early in drug discovery programs. The current high pressure to successfully develop new drugs is implying fast in silico and in vitro methodologies with the purpose of optimizing those particular pharmacokinetic properties of the prototypes (Hosea and Jones, 2013) . The in silico approach intends to simulate and predict the absorption, distribution, metabolism and excretion (ADME) properties of compounds, and it has gained an increase importance in the recent years. However these methodologies must be firstly validated and conjugated with in vivo results in order to adequately foresee the in vivo pharmacokinetics. Up to date, the information regarding the in vivo pharmacokinetic parameters of several derivatives of current AEDs is scarce and, when available, it results from distinct protocols, hampering data integration.
Thus, in an attempt to support and validate in silico pharmacokinetic-based drug design of novel and chemically related AEDs, this work was planned to acquire new in vivo data considering the systemic exposure, biodisposition and brain penetration of carbamazepine (CBZ) and nine derivatives after oral administration to mice. These in vivo pharmacokinetic data can also be incorporated in more complete and complex in silico models (Margineanu, 2012) in order to select those compounds that influence in vitro targets at appropriate concentrations and Page 5 of 32 A c c e p t e d M a n u s c r i p t 5 simultaneously exhibit acceptable bioavailability and brain penetration instead of selecting the candidate that best sticks only the pharmacodynamic target or the pharmacokinetic characteristics. The set of test compounds included not only clinically available drugs such as CBZ, oxcarbazepine (OXC) and eslicarbazepine acetate (ESL), but also S-licarbazepine (S-Lic), R-licarbazepine (R-Lic), carbamazepine-10,11-epoxide (CBZ-E), 10,11-trans-dihydroxy-10,11-dihydro-carbamazepine (trans-diol), BIA 2-024, BIA 2-059 and BIA 2-265. As shown in Figure   1 , all the compounds share the dibenz[b,f]azepine-5-carboxamide group. Furthermore, due to its influence on pharmacokinetics and pharmacodynamics, the plasma protein binding percentage was also determined for all the test compounds applying an in vitro methodology.
Material and Methods

Chemicals and reagents
OXC, ESL, CBZ-E, S-Lic, R-Lic, trans-diol, BIA 2-059, BIA 2-024 and BIA 2-265 were kindly supplied by BIAL (Porto, Portugal). CBZ, chloramphenicol and 10,11-dihydrocarbamazepine were purchased from Sigma-Aldrich (St Louis, MO, USA).
High performance liquid chromatography (HPLC) gradient grade methanol and acetonitrile were purchased respectively from Fisher Scientific (Leicestershire, UK) and Lab-Scan (Sowinskiego, Poland). Ultrapure water (HPLC grade, >15 MΩ) was obtained by means of a Milli-Q water apparatus from Millipore (Milford, MA, USA). Ethyl acetate, sodium dihydrogen phosphate dihydrate, di-sodium hydrogen phosphate dehydrate, sodium chloride, potassium dihydrogen phosphate and hydrochloric acid 37% were purchased from Merck KGaA (Darmstadt, Germany). Carboxymethylcellulose sodium salt for preparation of drug suspensions was obtained from Sigma (St. Louis, USA). heparinised tubes and centrifuged at 4000 rpm for 10 min at 4 ºC. Plasma supernatant was frozen at -30 ºC until analysis. After exsanguination, the brain was quickly excised, weighted and homogenised in a 0.1 M sodium phosphate buffer pH 5 (4 mL of buffer per g of tissue)
In vivo
using a THOMAS ® teflon pestle tissue homogenizer. The homogenates were centrifuged at 4800 rpm for 15 min at 4 ºC, originating supernatants that were also stored at -30 ºC until analysis.
Sample pre-treatment
Samples of mice plasma and brain homogenate were processed by a solid-phase extraction procedure based on methods previously published (Fortuna et al., 2011a (Fortuna et al., , 2011b ). An aliquot of plasma sample (300 µL) was added to 700 µL of 0.1 M sodium phosphate buffer (pH 5) and spiked with the adequate internal standard (IS) working solution, while each sample of brain homogenate supernatant (1 mL) was only spiked with IS. Samples were vortex-mixed and loaded into Oasis ® HLB cartridges (30 mg, 1 mL, Waters, Milford, MA, USA), previously conditioned with 1 mL of methanol, 1 mL of acetonitrile and 1 mL of water-acetonitrile (95:5, v/v). After sample elution, the loaded cartridges were submitted to -40 kPa and washed four times with 1 mL of water-methanol (90:10, v/v). After drying the sorbent, the analytes were eluted with 1 mL of ethyl acetate under a gentle vacuum. The eluates were evaporated to dryness under a nitrogen stream at 45 °C and the residues were reconstituted in 100 μL of HPLC mobile phase, transferred to a 0.22 μm Spin-X centrifugal filter and centrifuged at 13400 rpm for 2 min. Lastly 20 μL of the final filtered samples were injected into the HPLC system. (Fortuna et al., 2011a) . Similar conditions were used for the quantification of BIA 2-059, BIA 2-024, BIA 2-265 and their main metabolites (OXC, S-Lic, R-Lic) . Separation was carried at 35 ºC, with a mobile phase of water-methanol (92:8, v/v) pumped at 0.7 mL/min and using CBZ-E as IS; the LOQ was defined as 0.2 µg/mL and 0.06 µg/mL for all analytes in plasma and brain homogenate, respectively (Fortuna et al., 2011b) . The quantification of trans-diol in mice plasma and brain homogenate after its administration to the animals was attained by an achiral HPLC-UV method, adapted from another previously developed and validated technique (Fortuna et al., 2011a), using water-methanol-acetonitrile (64:30:6, v/v/v) , at a flow rate of 1 mL/min and a C 18 -reversed-phase column LiChroCART ® Purospher ® Star (Merck KGaA, Darmstadt, Germany). The 10,11-dihydrocarbamazepine was used as IS. The calibration range of trans-diol in the plasma and brain of mice were respectively 0.2-10 µg/mL and 0.06-0.30 µg/mL (r 2 ≥0.998).
Quantification of CBZ and derivatives in plasma and brain tissue
At LOQ levels, the precision (expressed as percentage of coefficient of variation) and accuracy (expressed by the deviation from nominal value in percentage) were, respectively, 13.6% and -1.25% in plasma and 2.7% and 15.2% in brain homogenate supernatants. The overall intra and inter-day precision was less than 9.50% and the intra and inter-day accuracy ranged from -11.19 to 1.86%.
Pharmacokinetic data analysis
The maximum peak concentration (C max A c c e p t e d M a n u s c r i p t
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In order to assess the extent of distribution of each compound to the brain, brain-to-plasma ratios were calculated considering C max , AUC 0-12h and AUC 0-∞ .
In vitro determination of plasma protein binding
The binding of the dibenz[b,f]azepine-5-carboxamide derivatives to mice plasma proteins was investigated in vitro by ultrafiltration (UF) experiments using a Microcon ® Ultracel YM-30 device with a cellulose membrane filter of 0.32 cm 2 and 30 kDa cut-offs (Millipore, Bedford, USA). The studies were performed at 40 µM for CBZ, 8 µM for OXC, 4 µM for CBZ-E, 100
µM for BIA 2-024 and BIA 2-265, 15 µM for trans-diol and 6 µM for ESL and BIA 2-059.
Stock solutions of each compound were prepared in DMSO and thereafter accurately diluted in Sorënsen buffer (pH 7.4) in order to obtain the correspondent spiking solution used in the assay.
Plasma aliquots of 1 mL (n = 4) were spiked with the correspondent quantity of drug and then incubated in a water bath under circular shake at a rate of 10 rpm, for 30 min, at 37 ºC.
Following incubation, 300 μL of plasma were used for the determination of the total concentration of each test compound and 500 μL were transferred to the Microcon ® Ultracel YM-30 UF device, sealed with the attached cap and centrifuged at 14000 rpm, 37 ºC, during 30 min. Afterwards, the concentration of the compound was determined in 300 µL of the ultrafiltrate, in order to obtain the unbound drug concentration. The analysis of these samples was performed by adapting the HPLC techniques described in section 2.2.3.
The PPB (%) obtained by UF was calculated considering the equation ( where C t corresponds to the total concentration in spiked plasma without having been subjected to UF and C f represents the free drug concentration obtained in the ultrafiltrates.
The non-specific binding (NSB) of each test compound to the filter membrane and plastic parts of the UF apparatus was assessed using spiked isotonic Sorënsen phosphate buffer instead of using spiked plasma. The NSB (%) was estimated according to the equation (2): where C tb refers to the total compound concentration in the spiked buffer without UF and C fb is the free drug concentration obtained in the corresponding filtrate after UF.
Correlation between pharmacokinetic parameters, physicochemical characteristics and PPB
Page 9 of 32 A c c e p t e d M a n u s c r i p t
9
The degree of association between the principal pharmacokinetic parameters (C max , AUC 0-12h and brain-to-plasma ratios) and molecular mass (MM), pKa, octanol-water partition coefficient (LogP), polar surface area (PSA) and PPB of drug candidates was investigated applying GraphPad Prism version 5.00 for Microsoft Windows (GraphPad Software, USA) to determine the Pearson's correlation coefficient (r) and a minimum p value of 0.05 was used as a significance level for the tests.
Results
Plasma disposition of CBZ and its derivatives
The plasma concentration-time profiles of the ten test compounds and respective main metabolites following their oral administration to mice are plotted in Figure 2 and the corresponding pharmacokinetic parameters estimated by non-compartmental analysis are summarized in Table 1 . In particular situations, the pharmacokinetic parameters could not be calculated because the compound was not detected in the sample or because it appeared below the LOQ of the analytical technique. Taking into account the t max values reported in Table 1 , it is evident that almost all the parent compounds reached the maximum peak plasma concentration until 1 h after oral administration, suggesting that the dibenz[b,f]azepine-5-carboxamide derivatives are rapidly absorbed through the gastrointestinal tract. BIA 2-024 was the only exception as it presented a t max of approximately 2 h and, therefore, it is regarded as the compound most slowly absorbed.
From the direct analysis of the profiles depicted in Figure 2 , it is clearly observed that CBZ-E, trans-diol and BIA 2-265 did not originate any other compound for which the bioanalytical techniques had been developed. In fact, no additional peaks appeared in the chromatograms beyond those that corresponded to the administered compound or IS. Among the other seven derivatives, BIA 2-024 was the less metabolized compound, exhibiting an AUC 0-12h that corresponded to approximately 98.6% of the total drug exposure in plasma. Indeed, BIA 2-024 originated R-Lic and S-Lic in a very small extent (< 2%), suggesting that the parent compound is considerably stable from the metabolic viewpoint and probably the main responsible for its anticonvulsant action. Like BIA 2-024, R-Lic, S-Lic and OXC also demonstrated to be very stable in mice, being present as 88.0%, 82.9% and 82.7% of the total systemic drug exposure (as assessed by AUC 0-12h ).
It is interesting to highlight the difference found between R-Lic and S-Lic; while S-Lic mainly originated OXC, R-Lic was metabolised in a lower extent than S-Lic, originating not only OXC but also measurable amounts of the eutomer (S-Lic). In opposition, CBZ, ESL and BIA 2-059 were the most extensively metabolized in mice. CBZ mainly originated CBZ-E considering the high C max and AUC 0-12h values reported for this metabolite after the administration of CBZ. Although other minor compounds were detected by the analytical method, they were not identified or quantified since the method was not validated for that purpose. Thus, and considering only the production of CBZ-E, both the parent compound and its main metabolite presented similar total drug exposure in plasma (approximately 50%). According to fact that, as a metabolite, CBZ-E is simultaneously produced and subjected to elimination processes while after its own administration, CBZ-E becomes immediately available in plasma presenting a t max value of 0.5 h and remaining less time in the body.
Analyzing BIA 2-059, it appears as the only parent compound that, when detected in plasma samples, exists at concentrations below the LOQ of the method (0.2 µg/mL). As depicted in Figure 2 , BIA 2-059 was rapidly metabolized to R-Lic, S-Lic and OXC which corresponded respectively to 88.8%, 1.0% and 10.2% of the total systemic drug exposure (as assessed by AUC 0-12h ) (Table 1) . However, when comparing BIA 2-059 with its enantiomer (ESL), a distinct pharmacokinetic profile was found not only for the parent compounds but also for their metabolites. ESL was mainly biotransformed to S-Lic (82.9%) and to a minor extent to OXC (16.8%) and R-Lic (0.21%). It is important to highlight that the extension of systemic exposure to S-Lic, R-Lic and OXC (assessed by AUC 0-12h ) were, respectively, 2.2%, 88.0% and 9.7% after the R-Lic administration, while the systemic exposure to S-Lic and OXC was respectively 82.9% and 17.1% after S-Lic administration (Table 1) . These values are similar to those described after the administration of ESL and BIA 2-059, supporting the view that each one of the acetate derivatives (ESL and BIA 2-059) is considered a prodrug of the corresponding alcohol compound.
Brain disposition and blood-brain distribution of CBZ and its derivatives
As the brain is the target organ of the AEDs, concentrations of the dibenz[b,f]azepine-5-carboxamide derivatives and main metabolites were also determined in mice brain homogenate after single oral administration of each compound at 1.4 mmol/kg. Figure 3 shows the mean brain concentration-time profiles of the various compounds and respective metabolites while the corresponding pharmacokinetic parameters are summarized in Table 2 .
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Globally analyzing the brain concentration-time profiles, the t max of several compounds was slightly displaced to the right in comparison to those observed in plasma. The exceptions included ESL, CBZ-E, OXC and BIA 2-024 that show, in both matrices, t max values of 0.5 h, 0.5 h, 1 h and 2 h, respectively. Similar findings were observed considering the t max values of the metabolites (Table 2 ). This may indicate that ESL, CBZ-E, OXC and BIA 2-024 cross the blood-brain barrier (BBB) more promptly than the remaining derivatives.
Similarly to the analysis aforementioned in the previous section regarding the metabolic stability of the compounds, the results presented in Table 2 demonstrated that OXC and BIA 2-024 still remained considerably stable in the brain accounting respectively for 96.26% and 90.10% of the total brain drug exposure. Moreover, the other compounds also demonstrated similar metabolic stability in the brain to that observed at systemic level.
It was also clear that the test compounds presented lower values of C max , AUC 0-12h and AUC 0-∞ in the brain than in plasma ( Figure 3 , Table 2 ). In order to assess the extent of distribution of each compound to the target organ, C max , AUC 0-12 and AUC 0-∞ brain/plasma ratios were calculated (Table 3) . None of these ratios could be calculated for BIA 2-059, for R-Lic after administration of S-Lic and for S-Lic after BIA 2-024 administration, because their plasma levels were below the LOQ of the bioanalytical methods. Some values of AUC 0-12h and AUC 0-∞ brain/plasma ratios could not be calculated due to the fact that their AUC values in brain were not possible to calculate. All the values of brain/plasma ratios calculated considering C max and AUC 0-12h were lower than 1.0 (Table 3 ), suggesting that the BBB restricts drug entry into the brain. Taking into account the ratios assessed by both pharmacokinetic parameters depicted in Table 3 , three groups of compounds could be distinguished. One is constituted by compounds with C max and AUC 0-12 ratios higher than 0.50 and includes OXC, CBZ, CBZ-E. Another group is characterized by at least one of the ratios values between 0.05 and 0.50 and includes S-Lic, RLic, trans-diol and BIA 2-024. Finally, there is BIA 2-265 for which the ratios are lower than 0.05.
Plasma protein binding of CBZ and its derivatives
The concentration used for measuring the PPB of each test compound was defined according to previous studies and included the therapeutic range of compounds (Fortuna et al., 2010 (Fortuna et al., , 2012b .
Once no saturation phenomenon was observed (Fortuna et al., 2012a) and, regarding that for ethical reasons in the present work we should only investigate one concentration, the middle concentration was chosen for each compound.
The NSB percentage of the ten dibenz[b,f]azepine-5-carboxamide derivatives to the UF device was lower than 5%. This result is considered negligible and, hence, no correction factor was applied to calculate the PPB by UF.
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The percentage of PPB found for each compound under in vitro conditions is depicted in 
Correlation between pharmacokinetic parameters, physicochemical characteristics and PPB
The physicochemical properties of the ten compounds herein under investigation are depicted in Table 5 . There was no correlation between plasmatic C max or AUC 0-12h with any physicochemical characteristic under study (MM, pKa, logP and PSA). However, the percentage of PPB did exhibit a significant correlation with C max (r = -0.900, p = 0.002) and or C max ratios when compared to logP, pKa or PPB.
Discussion
Therapeutic targets located within the brain represent unique challenges for drug discovery programs. Because of the tight endothelial junctions and efflux transporters expressed in the BBB, a common defiance encountered in oral AEDs discovery is the conversion of a potent compound with in vitro activity into a compound that reaches considerable levels in circulation and brain tissue, avoiding the lack of in vivo activity usually attributed to suboptimal pharmacokinetic characteristics (Partridge, 2003) .
Thus, the main purpose of this study was to report the pharmacokinetics of ten derivatives of CBZ after their oral administration to mice and determine their systemic bioavailability, brain/plasma partition ratio and PPB in order to evaluate whether the pharmacological differences between the ten derivatives of CBZ may be a consequence of their distinct systemic exposure and/or plasma-to-brain distribution. Simultaneously this data may be useful for supporting in silico models.
This is the first time that a wide set of dibenz[b,f]azepine-5-carboxamide derivatives is studied for a systemic and brain in vivo pharmacokinetic evaluation after oral administration to mice.
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Mouse was the specie herein chosen because rodents are generally used as a reference predictive animal model to evaluate the pharmacodynamics of drug candidates during the discovery of new AEDs applying the maximal electroshock seizure (MES) test (Castel-Branco et al., 2009 ).
In addition, mice were preferred in relation to rats based on in vivo and in vitro investigations which have revealed that the metabolism of ESL, CBZ, and BIA 2-024 in humans is more similar to that observed in mice than in rats (Hainzl et al., 2001; Hidaka et al., 2005; Alves et al., 2008a Alves et al., , 2008b . The single dose of 1.4 mmol/kg was chosen based on the fact that previous studies have revealed that this dose was associated with no significant toxicity and provided a systemic exposure to the active metabolite of OXC and ESL (S-Lic) comparable with those occurring in epileptic patients after treatment with therapeutic doses of OXC (González-Esquivel et al., 2000) and ESL (Bialer et al., 2004) . As the present research investigation intended to compare all the ten derivatives, an equimolar dose was maintained for the remaining compounds. Toxicity was not herein investigated because it falls outside the scope of the present work, however it must be emphasized that no animal died throughout the pharmacokinetic studies. The animals particularly administered with CBZ, OXC, ESL, S-Lic and BIA 2-024 were more sleepy and apathetic and only few animals administered with CBZ and CBZ-E showed some motor impairments which tended to disappear after 1 h post-dosing.
The analysis of the pharmacokinetic profiles herein carried out for the ten dibenz[b,f]azepine-5-carboxamide derivatives, clearly demonstrated that all of them were quickly absorbed from the mice gastrointestinal tract, except BIA 2-024. This particular compound presents an oxime moiety in 10 th position and reaches C max only 2 h after its administration, probably because it is slowly absorbed through the intestinal membrane. Interestingly, among all the derivatives, BIA 2-024 was the one that presented the lowest value of in vitro apparent permeability through mice intestine and the highest efflux ratio that is associated to its high affinity to the Pglycoprotein (Fortuna et al., 2012b) . These observations may hamper its oral absorption, contributing to the higher t max found for BIA 2-024 in comparison to the other test compounds.
Furthermore, together with the high metabolic stability herein observed for BIA 2-024, they may also explain the high value of its AUC 0-12h despite the slow intestinal absorption. These results are in agreement with other in vivo studies, as well as, with in vitro investigations performed in human liver microsomes (Hainzl et al., 2002) Due to its impact on the efficacy and safety of new chemical entities, metabolic stability should be early investigated to select and/or design AEDs. The metabolic stability herein is given by the AUC 0-12h ratio of the parent compound and the total systemic drug. Compounds poorly metabolized (e.g., BIA 2-024) originated high values of systemic drug exposure, which may allow larger intervals between administrations at the steady-state conditions. In opposition,
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A c c e p t e d M a n u s c r i p t 14 compounds extensively metabolized may originate high quantities of toxic derivatives and diminish the therapeutic index of the parent compound. For instance, CBZ, which is well known for its considerable neurological and motor toxicity in humans ascribed to the metabolite CBZ-E (Myllynen et al., 2002; Spina, 2002) , presented the lowest value of effective dose for protecting 50% of the rats (ED 50 ) against MES-induced seizures and the lowest median toxic dose (TD 50 ) in the rotarod test (Ambrósio et al., 2002; Benes et al., 1999; Bonifácio et al., 2001 ). This means that, at lower concentrations, CBZ develops motor impairment that is not observed for the other compounds and its protective index (given by the ratio between ED 50 and TD 50 ) is considerably lower in relation to OXC, ESL, S-Lic, R-Lic, BIA 2-059 and BIA 2-024 (Benes et al., 1999; Bonifácio et al., 2001; Learmonth et al., 2001 ). These in vivo pharmacodynamic behaviours are strongly supported by our results which revealed that CBZ was the only dibenz[b,f]azepine-5-carboxamide derivative extensively metabolized to CBZ-E. This is evidenced by the high values of AUC 0-12h , t 1/2 and MRT of CBZ-E in plasma and brain after CBZ administration, favouring the accumulation of the metabolite in brain for such a long time that may induce the remarkable toxicity observed in vivo.
On the other hand, in vivo, OXC showed a higher protective index than CBZ in spite of its higher toxicity observed in vitro (Araújo et al., 2004) . This apparent discrepancy might be explained by the fact that, in vivo, OXC has yielded a metabolite (S-Lic) that is more innocuous than the major metabolite of CBZ. However, the protection conferred by OXC against MESinduced seizures in rats is lower than that obtained after ESL administration (Benes et al., 1999) . Considering the results reported herein, this may be due to the fact that ESL is rapidly and extensively metabolized to S-Lic, which bioavailability measured in terms of AUC 0-12h was approximately 6 times greater than that obtained after oral intake of an equimolar dose of OXC (Table 2 ).
The metabolism also has impact when considering two dibenz[b,f]azepine-5-carboxamide derivatives that are enantiomers (ESL and BIA 2-059). The bioavailability of S-Lic after oral administration of BIA 2-059 to mice was significantly lower than that obtained after ESL or OXC administration. Interestingly, this finding may explain the considerable lower protective index of BIA 2-059 against MES-induced seizures in rats, compared to that of ESL, in spite of their in vitro similar ability to inhibit the sodium uptake into cortical synaptosomes (Benes et al., 1999; Hainzl et al., 2001 ).
All the aforementioned findings clearly sustain that the t max , bioavailability (given by AUC 0-12h ) and metabolic stability of dibenz[b,f]azepine-5-carboxamide derivatives must be considered primary parameters to be investigated in parallel with in vitro and in vivo pharmacodynamics because they clearly determined the pharmacological activity in vivo.
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Additionally, when the targeted site of action lies within the CNS, the BBB represents a relevant barrier for the access of compounds to the target organ and it is frequently responsible for the relatively low success rate in discovery and development of CNS drugs (Partridge, 2005) . For instance, in vitro it was demonstrated that BIA 2-024 had a higher potency to bind to sodium channels and modulate sodium entry than CBZ. However, in vivo, it is as effective as CBZ and OXC at controlling seizures (Ambrósio et al., 2001; 2002; Benes et al., 1999; Learmonth et al., 2001) . Although this may seem contradictory, the low brain-to-plasma ratios herein obtained for BIA 2-024 in relation to those obtained for CBZ and the slower absorption of BIA 2-024 may justify its potency in vivo.
The stereoselective brain disposition of S-Lic and R-Lic is also noteworthy. As they are enantiomers, differing only in their spatial configuration (Figure 1 ) and in their ability to rotate plane-polarized light, it was expected that S-Lic and R-Lic would show similar t 1/2 , C max and AUC 0-12h brain/plasma ratios. Nevertheless, the pharmacokinetic parameters obtained after in vivo administration of S-Lic or R-Lic to mice showed differences equal to or higher than 20% (Tables 2 and 3 ) and the brain/plasma ratios of S-Lic were approximately twice of those of RLic (0.25 versus 0.11 considering the C max and 0.55 versus 0.26 considering the AUC 0-12h ).
These findings suggest a larger distribution of the eutomer (S-Lic) to the brain. Since the percentage of PPB of both enantiomers is similar (Table 4) , it is highly probable that they have different affinities for multidrug efflux transporters at the BBB, including P-glycoprotein.
Indeed, P-glycoprotein is normally expressed not only in the intestinal membrane but also on the luminal cell membrane of endothelial cells of BBB, reducing the brain disposition of drugs that interact with it (Fortuna et al., 2011c) . Importantly, this transporter has been found to be over-expressed in endothelial cells, neurons and glial cells from human drug-resistance epileptic brain tissue, enhancing the extrusion of AEDs from brain to bloodstream and consequently lowering the brain concentration of several AEDs below effective (Aronica et al., 2012; Zhang et al., 2012) . At this point, we have recently carried out in vitro studies to investigate the affinity of Lic enantiomers to P-glycoprotein and the results clearly revealed that R-Lic was likely to be transported by P-glycoprotein, in opposition to S-Lic (Fortuna et al., 2012b) . Even though the experimental in vivo study herein described did not intend to analyse the P-glycoprotein influence on drug brain penetration, it is quite probable that the differences observed in vivo regarding the brain disposition of both enantiomers involve particularly this efflux transporter.
Considering the PPB obtained in vitro for the set of compounds herein under investigation, BIA 2-265 stands out as the only one that binds to plasma proteins in a percentage higher than 90%.
Probably, the low unbound fraction of BIA 2-265 may have significantly contributed to the reduced brain disposition of the drug observed in vivo (Table 3) is not a major determinant of brain penetration, unless it is greater than 90%, such as for BIA 2-265.
The effect of molecular properties on the primary pharmacokinetic parameters (C max and AUC 0-12h ) and on the brain/plasma ratios was also herein considered. Particularly MM, logP, pKa and PSA were chosen not only because they are easily accessible but also because they represent major determinants of brain penetration of compounds (Partridge, 2005; Zhao et al., 2009 ).
Generally, small, lipophilic, non-charged drugs diffuse more easily by passive transcellular mechanisms than the hydrophilic ones. In addition, only the free fraction of drug is available to cross the BBB (Lange et al., 2005) and a high lipophilicity also makes compounds more vulnerable to bind to plasma and efflux proteins (Perisic-Janjic et al., 2011) . Based on the correlation analysis herein reported, it is important to emphasize that MM and PSA appeared to be the most important determinants of brain/plasma ratios and the AUC 0-12h and C max values obtained in brain were also strongly correlated with PSA. Even though PPB did not correlated with brain-to-plasma ratios or pharmacokinetic profile in brain, it must be underlined that when it is higher than 90% (such in case of BIA 2-265) it may compromise brain penetration since only the plasmatic free fraction is available to cross the BBB and reach the target organ of AEDs.
In the in vivo pharmacokinetic evaluation herein performed, the relative systemic and brain exposure of CBZ and derivatives were, incontestably, linked to their pharmacodynamic and efficacy/toxicity readouts. Therefore, the sooner plasma and biophase pharmacokinetic information is obtained the less costly and risky is the discovery of AEDs. Moreover, it was demonstrated that PPB compromised the brain penetration of these compounds when higher than 90%; otherwise it had no influence. This would be very interesting to apply during the discovery phase of new AEDs derivatives of CBZ, as it would allow the development of compounds with higher probability of having adequate brain penetration. Nevertheless, it cannot be forgotten that, in parallel to this pharmacokinetic evaluation, additional tests in in vivo seizure-induced animal models must be performed in order to evaluate the drug efficacy, toxicity and protective effects.
Overall, it was evident that CBZ, CBZ-E and OXC presented the highest values of brain/plasma ratios and probably that fact sustains their pharmacological activity at the cerebral level. It is extremely interesting to point out that the in vitro methodologies previously developed within our research group (Fortuna et al., 2012a (Fortuna et al., , 2012b ) also demonstrated that CBZ, OXC and CBZ-E were the most permeable compounds though artificial and biological barriers, which is in agreement with the in vivo results herein presented.
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Conclusions
The present in vivo studies clearly evidenced that the t max , the extent of brain penetration and the metabolic stability of dibenz[b,f]azepine-5-carboxamide derivatives must be considered as primary parameters to be investigated in parallel with in vitro and in vivo pharmacodynamics because they clearly determine the in vivo activity. The comparative in vivo pharmacokinetic data obtained based on the protocol herein applied, together with those obtained through the in vitro approaches previously described by Fortuna et al (2012a Fortuna et al ( , 2012b and those of the in vitro and in vivo evaluation of efficacy and protective effects, may be useful for developing predictive in silico pharmacokinetic-based models that can be applied in the earlier stages of the discovery of new derivatives of CBZ. Pharmacological Reports, 61, [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] A c c e p t e d M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Values represent mean ± standard deviation (n = 4)
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